Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „denosumab“
Suchtreffer
Begriffe & Kennungen
Jubbonti · 4.8 · The most common adverse reactions with denosumab (seen in more than one patient in ten) are musculoskeletal pa
Eintrag öffnenObodence · 4.5 · In an interaction study, denosumab did not affect the pharmacokinetics of midazolam, which is metabolised by c
Eintrag öffnenObodence · 4.5 · In postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of denosumab were not alte
Eintrag öffnenObodence · 4.5 · There are no clinical data on the co-administration of denosumab and hormone replacement therapy (oestrogen),
Eintrag öffnenObodence · 4.8 · Paediatric population Denosumab should not be used in paediatric patients (age < 18). Serious hypercalcaemia h
Eintrag öffnenObodence · 4.8 · The most common side effects with denosumab (seen in more than one patient in ten) are musculoskeletal pain an
Eintrag öffnenOsenvelt · 4.5 · In clinical trials, denosumab has been administered in combination with standard anti-cancer treatment and in
Eintrag öffnenOsenvelt · 4.8 · 8 The trials in patients with breast or prostate cancer included a denosumab extension treatment phase (median
Eintrag öffnenOsenvelt · 4.8 · A grade 3 decrease in serum calcium levels was experienced in 2.5% of patients treated with denosumab and 1.2%
Eintrag öffnenOsenvelt · 4.8 · A higher incidence of ONJ among patients treated with denosumab compared to zoledronic acid has been observed
Eintrag öffnenOsenvelt · 4.8 · A non-randomised, retrospective, observational study in 2,877 patients with cancer treated with denosumab or z
Eintrag öffnenOsenvelt · 4.8 · Accompanying increases in parathyroid hormone have also been observed in patients receiving denosumab with sev
Eintrag öffnenOsenvelt · 4.8 · Denosumab was studied in an open-label trial that enrolled 28 skeletally mature adolescents with giant cell tu
Eintrag öffnenOsenvelt · 4.8 · Hypocalcaemia A higher incidence of hypocalcaemia among patients treated with denosumab compared to zoledronic
Eintrag öffnenOsenvelt · 4.8 · Hypocalcaemia has very commonly been reported following denosumab administration, mostly within the first 2 we
Eintrag öffnenOsenvelt · 4.8 · In a phase III trial in patients with non-metastatic prostate cancer (a patient population for which denosumab
Eintrag öffnenOsenvelt · 4.8 · Overall safety profile is consistent in all approved indications for denosumab.
Eintrag öffnenOsenvelt · 4.8 · The cumulative incidence at one year was 1.1% for denosumab and 0.6 % for zoledronic acid, respectively.
Eintrag öffnenProlia · 4.5 · In an interaction study, denosumab did not affect the pharmacokinetics of midazolam, which is metabolised by c
Eintrag öffnenProlia · 4.5 · In postmenopausal women with osteoporosis the pharmacokinetics and pharmacodynamics of denosumab were not alte
Eintrag öffnen